Constellation Pharmaceuticals Initial Public Offering
7/26/2018

Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public offering of common stock of Constellation Pharmaceuticals, Inc. The common stock is listed on the NASDAQ Global Select Market under the symbol “CNST.”

Based in Cambridge, Massachusetts, Constellation is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance.

The Davis Polk capital markets team included partners Richard D. Truesdell Jr. and Marcel Fausten and associates Cameron C. Lewis, Matthew M. Funk and Jae Maeng. Partner David R. Bauer and associates Bonnie Chen and Christopher C. Woller provided intellectual property and technology advice. Partner William A. Curran and associate Alexander J. Hendin provided tax advice. All members of the Davis Polk team are based in the New York office.